Biosimilar Monoclonal Antibodies Market | Size, Share and Scope Analysis to 2031

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Biosimilar Monoclonal Antibodies Market- by Product (Infliximab, Trastuzumab, Rituximab, Adalimumab, Bevacizumab, Cetuximab, Ranibizumab, Denosumab, Eculizumab and Other Pipeline Products), Indication (Oncology, Inflammatory & Autoimmune Disorders, Chronic Diseases, Blood Disorders and Other Indication), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

Get Free Sample Copy of Report : https://www.insightaceanalytic.com/request-sample/1218 

According to the latest research by InsightAce Analytic, the global Biosimilar Monoclonal Antibodies market is valued at US$ 4.98 Billion in 2022. It is expected to reach US$ 36.85 Billion by 2031, with a CAGR of 25% during a forecast period of 2023-2031.

The production of monoclonal antibodies (mAb) involves employing identical immune cell clones of a single original parent cell. Because all monoclonal antibodies produced by a parent cell are similar since they are all clones of the same parent cell, they are referred to as biosimilar monoclonal antibodies. Biotherapeutic items include biosimilars.

In terms of quality, effectiveness, and safety, they are comparable to cutting-edge reference pharmaceutical products. The mAb biosimilars are sophisticated biological macromolecules that have undergone several post-translational changes. Numerous autoimmune, inflammatory, and chronic disorders are treated effectively with these biosimilars.

The rising production of advanced monoclonal antibodies, the rising geriatric population, and the high prevalence of chronic diseases like cancer, kidney failure, rheumatoid arthritis, psoriasis, diabetes, and others are all contributing factors to the growth of the global market for biosimilar monoclonal antibodies. As more mAbs' patents expire, more chances for market expansion are anticipated over the coming years.

The demand for mAbs is anticipated to grow quickly throughout the forecast period due to increased patent expirations of the most popular antibodies. However, the complexity of producing biological pharmaceuticals, the lack of clinical trial experience, the tight government rules for product approvals, and the lack of awareness and understanding among manufacturers concerning biosimilar regulation and approval are all predicted to impede the market's growth.

North America is anticipated to be the major contributor to the Biosimilar Monoclonal Antibodies market over the forecast years. The region's strong growth can be ascribed to increased product approvals, a well-established health care infrastructure, and a favorable reimbursement scenario. In addition, the Asia Pacific regional market is expected to register significant growth during the estimated period because chronic disease burden, the need for affordable therapies, and government funding for healthcare facility improvements are all on the rise.

Major market players operating in the Biosimilar Monoclonal Antibodies market include

BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia), Dr. Reddys Laboratories Ltd (Hyderabad), 3SBio (China), Reliance Life Sciences (India), Hisun Pharma (China), Celgen Biopharma (China), Torrent Pharmaceuticals (Ahmedabad), Cadila Healthcare (Cadila Healthcare), Mylan Inc. (US) and others.

Recent collaborations and agreements in the market:

In July 2021, Abzena (UK), a global partner research organization for biologics and bioconjugates, and BioXpress Therapeutics (Switzerland) collaborated to support third-party biosimilar development. This collaboration resulted in an integrated solution by two prominent service providers in biosimilar development and GMP manufacturing.

In February 2021, Mylan (US) introduced Ogivri, a trastuzumab biosimilar. Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer, previously sold as Herceptin by Genentech.

Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1218 

Market Segments

Global Biosimilar Monoclonal Antibodies Market, by Product, 2023-2031 (Value US$ Mn)

Infliximab
Trastuzumab
Rituximab
Adalimumab
Bevacizumab
Cetuximab
Ranibizumab
Denosumab
Eculizumab
Other Pipeline Products

Global Biosimilar Monoclonal Antibodies Market, by Indication, 2023-2031 (Value US$ Mn)

Oncology
Inflammatory & Autoimmune Disorders
Chronic Diseases
Blood Disorders
Other Indication

Global Biosimilar Monoclonal Antibodies Market, by Region, 2023-2031 (Value US$ Mn)

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

North America Biosimilar Monoclonal Antibodies Market, by Country, 2023-2031 (Value US$ Mn)

U.S.
Canada

Europe Biosimilar Monoclonal Antibodies Market, by Country, 2023-2031 (Value US$ Mn)

Germany
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 2023-2031 (Value US$ Mn)

India
China
Japan
South Korea
Australia & New Zealand

Latin America Biosimilar Monoclonal Antibodies Market, by Country, 2023-2031 (Value US$ Mn)

Brazil
Mexico
Rest of Latin America

Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 2023-2031 (Value US$ Mn)

GCC Countries
South Africa
Rest of Middle East & Africa

Why should buy this report:

To receive a comprehensive analysis of the prospects for the global Biosimilar Monoclonal Antibodies market
To receive an industry overview and future trends of the Biosimilar Monoclonal Antibodies market
To analyze the Biosimilar Monoclonal Antibodies market drivers and challenges
To get information on the Biosimilar Monoclonal Antibodies market value (US$ Mn) forecast to 2030
Significant investments, mergers & acquisitions in the Biosimilar Monoclonal Antibodies market industry

For More Information @ https://www.insightaceanalytic.com/customisation/1218

InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: https://www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Follow Us @ https://www.linkedin.com/company/insightace-analytic-pvt-ltd/

Subscribe Our Exclusive Newsletters @ https://www.linkedin.com/newsletters/latest-market-research-reports-6929319878155739136/

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.